Agilent Technologies (NYSE:A) Issues Earnings Results, Beats Expectations By $0.05 EPS

Agilent Technologies (NYSE:A - Get Free Report) posted its quarterly earnings results on Wednesday. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.26 by $0.05, Zacks reports. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.63 billion. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The firm's revenue was up 6.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.22 EPS. Agilent Technologies updated its FY 2025 guidance to 5.540-5.610 EPS and its Q3 2025 guidance to 1.350-1.370 EPS.

Agilent Technologies Stock Down 1.3%

Shares of A stock traded down $1.45 during trading hours on Friday, reaching $111.83. 4,751,122 shares of the company's stock were exchanged, compared to its average volume of 1,929,518. Agilent Technologies has a 1 year low of $96.43 and a 1 year high of $153.84. The company has a current ratio of 2.09, a quick ratio of 1.66 and a debt-to-equity ratio of 0.55. The stock has a market cap of $31.88 billion, a PE ratio of 27.61, a PEG ratio of 3.17 and a beta of 1.27. The stock's fifty day moving average price is $108.44 and its two-hundred day moving average price is $126.41.

Agilent Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 23rd. Shareholders of record on Tuesday, July 1st will be issued a $0.248 dividend. This represents a $0.99 annualized dividend and a yield of 0.89%. The ex-dividend date is Tuesday, July 1st. Agilent Technologies's dividend payout ratio is presently 24.44%.

Analysts Set New Price Targets

A number of analysts recently issued reports on A shares. UBS Group lowered their price target on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a report on Thursday. Leerink Partners upped their target price on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a report on Friday. JPMorgan Chase & Co. cut their price target on Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating on the stock in a research note on Thursday. Wells Fargo & Company dropped their target price on shares of Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating on the stock in a report on Thursday, April 17th. Finally, TD Cowen raised their target price on shares of Agilent Technologies to $150.00 and gave the company a "buy" rating in a research report on Thursday. Seven investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Agilent Technologies has a consensus rating of "Moderate Buy" and an average target price of $140.15.

Insider Activity at Agilent Technologies

In related news, VP Rodney Gonsalves sold 1,908 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $121.98, for a total value of $232,737.84. Following the completion of the transaction, the vice president now owns 21,786 shares in the company, valued at $2,657,456.28. This trade represents a 8.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Daniel K. Podolsky sold 1,819 shares of the business's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $116.46, for a total value of $211,840.74. Following the sale, the director now owns 35,737 shares in the company, valued at approximately $4,161,931.02. The trade was a 4.84% decrease in their position. The disclosure for this sale can be found here.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Brighton Jones LLC lifted its holdings in shares of Agilent Technologies by 6.1% in the 4th quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company's stock valued at $626,000 after buying an additional 270 shares during the period. Acadian Asset Management LLC lifted its holdings in Agilent Technologies by 16.5% in the first quarter. Acadian Asset Management LLC now owns 5,352 shares of the medical research company's stock valued at $625,000 after acquiring an additional 758 shares during the period. Jones Financial Companies Lllp boosted its position in Agilent Technologies by 15.9% in the 1st quarter. Jones Financial Companies Lllp now owns 5,610 shares of the medical research company's stock worth $602,000 after purchasing an additional 769 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its stake in shares of Agilent Technologies by 54.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 599 shares of the medical research company's stock worth $70,000 after purchasing an additional 212 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.